Case presentation
A 56-year-old male patient with a history of Friedreich ataxia was referred to the cardiac catheterization laboratory after electromechanical resuscitation due to ventricular fibrillation. Two hours before, trans-urethral intra-vesical botulinum toxin A injection (300 units) had been performed because of neurogenic bladder dysfunction.
His past medical history was positive for hypertension and smoking, but negative for any cardiovascular event.
On admission, laboratory analysis had been unremarkable and baseline ECG showed incomplete right bundle branch block and T-wave inversions in leads V1-V2.
Postrescuscitation, new preterminal T-wave inversions were noted in the inferior leads and in leads I, and V3-6, along with troponin T elevation (0.72 µg/l). In the course, dynamic discrete ST-segment elevations developed in leads V1-V3. 
Discussion
We describe a case of acute myocardial infarction in a patient with Friedreich ataxia following intra-vesical botulinum toxin A injection.
Cardiac involvement is frequently observed in Friedreich ataxia. However, acute coronary syndromes have rarely been described in these patients. Typically, hypertrophic cardiomyopathy, which was excluded in our patient using echocardiography, and an abnormal repolarization phase and arrhythmias are detected (1).
Botulinum toxin A impedes neuromuscular transmission causing muscle weakening. It blocks acetylcholine release in nerve terminals by cleaving SNARE proteins, thereby preventing fusion of acetylcholine vesicles with the cell membrane.
Botulinum toxin A is widely used for cosmetic applications, in the treatment of muscle spasms, chronic pain syndroms, or bladder dysfunction (2).
Botulinum toxin A is assumed to have mainly local effects. However, systemic side effects have been described. Hence, botulinum toxin A might also affect vasoreactivity or interact with the coagulation cascade, endothelial cells or platelets and in turn promote thrombus formation. Indeed, single cases of myocardial infarction, pulmonary embolism, and even death have been reported after botulinum toxin A injection (3). The effect of botulinum toxin A on vasoreactivity is not fully understood. In rat aortic rings suspended in organ chambers, contractions to KCl and norepinephrine were completely inhibited after incubation with botulinum toxin (4).
Furthermore, in Sprague-Dawley rats, femoral vessel diameter was increased after subcutaneous botulinum toxin injection (5) . Hence, and in line with the coronary angiogram, vasospasms as the primary cause of the acute myocardial infarction appear unlikely in this patient. Rather, the extensive thrombus burden, suggests a pro-thrombotic state. As we did not exclude a patent foramen ovale in our patient, paradoxical embolism can not be ruled out completely. However, such events are rare and typically present with abrupt distal coronary occlusion suggestive of embolism on angiogram. In any case, pro-thrombotic effects of botulinum toxin A have not been described so far, both, in vitro and in vivo, and may be assumed.
The temporal coincidence of botulinum toxin injection and the onset of myocardial infarction in our patient suggest a causal relationship. Importantly, as botulinum toxin injections are widely performed, also in elderly patients with cardiovascular disease, and as acute coronary syndromes are serious complications, clinicians should be cautious using botulinum toxin A because of the risk of serious side effects and patients have to be monitored carefully after botulinum toxin injections. 
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